|
|
| (9 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Atorvastatin#Adult Indications and Dosage]] |
| {{Atorvastatin}}
| |
| {{CMG}}; {{AE}} {{PB}}
| |
| | |
| ==Indications and Usage==
| |
| | |
| Atorvastatin is an inhibitor of [[HMG-CoA reductase]] (statin) indicated as an adjunct therapy to diet to:
| |
| | |
| * Reduce the risk of [[MI]], [[stroke]], revascularization procedures, and [[angina]] in patients without [[CHD]], but with multiple risk factors.
| |
| * Reduce the risk of [[MI]] and [[stroke]] in patients with type 2 [[diabetes]] without [[CHD]], but with multiple risk factors.
| |
| * Reduce the risk of non-fatal [[MI]], fatal and non-fatal [[stroke]], revascularization procedures, hospitalization for CHF, and [[angina]] in patients with [[CHD]].
| |
| * Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed [[dyslipidemia]].
| |
| * Reduce elevated TG in patients with [[hypertriglyceridemia]] and primary dysbetalipoproteinemia.
| |
| * Reduce total-C and LDL-C in patients with homozygous familial [[hypercholesterolemia]] (HoFH).
| |
| * Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial [[hypercholesterolemia]] after failing an adequate trial of diet therapy.
| |
| ===Limitations of Use===
| |
| | |
| Atorvastatin has not been studied in Fredrickson Types I and V [[dyslipidemia]]s. | |